Prescription Drug Supply Chain Pricing Transparency Act

Hozzl · 2026-02-20T11:08:20Z

Explore the details of Senate Bill 3751 Prescription Drug Supply Chain Pricing Transparency Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

2/20/2026, 11:08 AM

Summary of Bill S 3751

The "Prescription Drug Supply Chain Pricing Transparency Act" was introduced in the 119th Congress as Senate Bill 3751 on January 29, 2026. The bill aims to enhance transparency in the pricing of prescription drugs within the supply chain. Specific directives or provisions detailed in the bill include measures to increase visibility into pricing mechanisms and costs associated with the production and distribution of prescription medications. For further information, the official text of the bill can be accessed at https://www.congress.gov/119/bills/s3751/BILLS-119s3751is.pdf.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3751

Bill S 3751 is currently in the status of Bill Introduced since January 29, 2026. Bill S 3751 was introduced during Congress 119 and was introduced to the Senate on January 29, 2026. Bill S 3751's most recent activity was Read twice and referred to the Committee on Finance. as of January 29, 2026

Bipartisan Support of Bill S 3751

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3751

Primary Policy Focus

Alternate Title(s) of Bill S 3751

A bill to require the Comptroller General of the United States to conduct a study and submit a report on price-related compensation and payment structures in the prescription drug supply chain.